share_log

Merck & Co | 4: Statement of changes in beneficial ownership of securities-10% Owner Merck & Co., Inc.

默沙東 | 4：持股變動聲明-股東 Merck & Co., Inc.

SEC announcement ·  03/12 03:32
牛牛AI助理已提取核心訊息
Merck & Co., Inc. has engaged in a significant transaction involving the purchase of Harpoon Therapeutics, Inc. (HARP) common stock. On March 11, 2024, Merck & Co. acquired 21,397,205 shares of Harpoon Therapeutics at a price of $23.00 per share. Following this transaction, Merck & Co. holds a total of 1,000 shares in Harpoon Therapeutics. The transaction is currently in progress and reflects a direct ownership type, as indicated in the acquisition log.
Merck & Co., Inc. has engaged in a significant transaction involving the purchase of Harpoon Therapeutics, Inc. (HARP) common stock. On March 11, 2024, Merck & Co. acquired 21,397,205 shares of Harpoon Therapeutics at a price of $23.00 per share. Following this transaction, Merck & Co. holds a total of 1,000 shares in Harpoon Therapeutics. The transaction is currently in progress and reflects a direct ownership type, as indicated in the acquisition log.
默沙東公司參與了一項涉及收購Harpoon Therapeutics, Inc.（HARP）普通股的重大交易。2024 年 3 月 11 日，默沙東公司以每股 23.00 美元的價格收購了 Harpoon Therapeutics 的 21,397,205 股股票。在這筆交易之後，默沙東公司共持有Harpoon Therapeutics的1,000股股份。如收購記錄所示，該交易目前正在進行中，屬於直接所有權類型。
默沙東公司參與了一項涉及收購Harpoon Therapeutics, Inc.（HARP）普通股的重大交易。2024 年 3 月 11 日，默沙東公司以每股 23.00 美元的價格收購了 Harpoon Therapeutics 的 21,397,205 股股票。在這筆交易之後，默沙東公司共持有Harpoon Therapeutics的1,000股股份。如收購記錄所示，該交易目前正在進行中，屬於直接所有權類型。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。